US 9,809,859 B2
Biomarkers for subtypes of cervical cancer
Heidi Lyng, Lommedalen (NO); and Malin Lando, Oslo (NO)
Assigned to OSLO UNIVERSITETSSYKEHUS HF, Oslo (NO)
Filed by Oslo universitetssykehus HF, Oslo (NO)
Filed on Mar. 20, 2015, as Appl. No. 14/664,346.
Application 14/664,346 is a division of application No. 13/045,671, filed on Mar. 11, 2011, abandoned.
Claims priority of provisional application 61/312,875, filed on Mar. 11, 2010.
Prior Publication US 2015/0197818 A1, Jul. 16, 2015
Int. Cl. C12Q 1/68 (2006.01); G01N 33/574 (2006.01)
CPC C12Q 1/6886 (2013.01) [G01N 33/57411 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); G01N 2333/4703 (2013.01); G01N 2333/4704 (2013.01); G01N 2333/4706 (2013.01); G01N 2333/91131 (2013.01)] 9 Claims
 
1. A method for detectably labelling a set of gene products from a human cervical cancer sample comprising:
isolating RNA from a human cervical cancer sample from a patient with locally advanced cervical cancer and reverse transcribing said isolated RNA to provide complementary DNA corresponding to at least three gene products selected from the group consisting of RYBP, GBE1, ALG5, FAM48A, COG6, KIAA1704, GTF2F2, MED4, RNASEH2B and PRDM15 gene products
amplifying said complementary DNA by polymerase chain reaction with primers specific for complementary DNA corresponding to at least three gene products selected from the group consisting of RYBP, GBE1, ALG5, FAM48A, COG6, KIAA1704, GTF2F2, MED4, RNASEH2B and PRDM15 gene products in the presence of a probe to provide detectably labeled amplified complementary DNA;
quantitating the expression of said at least three gene products selected from the group consisting of RYBP, GBE1, ALG5, FAM48A, COG6, KIAA1704, GTF2F2, MED4, RNASEH2B and PRDM15 gene products; and
providing a prognosis based on the expression of said at least three gene products selected from the group consisting of RYBP, GBE1, ALG5, FAM48A, COG6, KIAA1704, GTF2F2, MED4, RNASEH2B and PRDM15 gene products.